[DOI] [PMC free article] [PubMed] [Google Scholar] 152.Yamanaka M., Shirai M., Shiina H., Tanaka Y., Tsujimura A., Matsumiya K., Okuyama A., Dahiya R
Cancers (Basel) 15, 3182
Moreover, in light of the growing evidence demonstrating the benefits of incretin-based therapies on both metabolic health and cardiovascular diseases, regulatory agencies such as the Food Drug Administration (FDA) and the European Medicines Agency (EMA) have approved their use for type 2 diabetes, reduction of cardiovascular risk and for chronic weight management in patients with morbid obesity [58]
Have contraindications or high-risk medical history: GLP-1 medications are not appropriate for everyone
10.1111/ene.13439 79 LaneD
Preliminary results with retatrutide from TRIUMPH-4 in participants with obesity or overweight and osteoarthritis